Prime Capital Investment Advisors LLC lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 8.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 47,158 shares of the company’s stock after buying an additional 3,593 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Merck & Co., Inc. were worth $6,853,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently made changes to their positions in the company. Horizons Wealth Management acquired a new stake in Merck & Co., Inc. in the third quarter valued at approximately $30,000. Bullseye Investment Management LLC bought a new stake in shares of Merck & Co., Inc. in the 2nd quarter worth $27,000. Graney & King LLC grew its position in Merck & Co., Inc. by 400.0% in the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after purchasing an additional 200 shares in the last quarter. Montgomery Financial Services LLC bought a new position in shares of Merck & Co., Inc. in the second quarter valued at approximately $41,000. Finally, Evergreen Advisors LLC bought a new position in Merck & Co., Inc. in the 1st quarter valued at $43,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.
Key Stories Impacting Merck & Co., Inc.
Here are the key news stories impacting Merck & Co., Inc. this week:
- Positive Sentiment: Merck’s newer cancer treatments and encouraging Phase 3 melanoma results may help broaden its oncology franchise and reduce reliance on Keytruda. Investors are assessing whether these products can become meaningful growth drivers before Keytruda faces patent-related competition. How Investors Are Reacting To Merck Phase 3 Melanoma Results
- Positive Sentiment: The company’s diversified drug portfolio, research investments and dividend—approximately a 2.4% yield—provide support for investors seeking income while waiting for newer therapies to offset future Keytruda pressure. Merck also previously raised its 2026 sales outlook. Merck’s 2.4% Dividend Yield
- Neutral Sentiment: Merck KGaA agreed to acquire Silence Therapeutics for approximately $1.3 billion in cash, including $20 per American depositary share. The deal could strengthen the German company’s pipeline, but Merck KGaA is a separate company from U.S.-listed Merck & Co. (MRK), so the transaction does not directly affect MRK’s earnings or stock.
- Negative Sentiment: Keytruda’s concentration creates a significant patent-cliff risk. New treatments must scale rapidly enough to replace a large portion of sales and profits when competition arrives, adding uncertainty to Merck’s valuation and long-term growth outlook. Merck Has New Cancer Treatments
- Negative Sentiment: Exchange-traded funds were reported as net sellers of MRK, indicating some short-term institutional or systematic selling pressure despite the company’s underlying growth initiatives. ETFs Are Net Sellers of Merck
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on MRK. Wall Street Zen downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Jefferies Financial Group lifted their target price on Merck & Co., Inc. from $152.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Royal Bank Of Canada decreased their price target on shares of Merck & Co., Inc. from $150.00 to $145.00 and set a “sector perform” rating on the stock in a report on Monday, October 12th. Citigroup upped their price objective on shares of Merck & Co., Inc. from $125.00 to $145.00 and gave the stock a “neutral” rating in a research report on Monday, October 12th. Finally, CICC Research initiated coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price on the stock. Seventeen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $151.92.
Check Out Our Latest Stock Analysis on MRK
Insider Transactions at Merck & Co., Inc.
In other news, EVP David Maraldo sold 18,706 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the transaction, the executive vice president owned 18,212 shares in the company, valued at $2,344,248.64. This trade represents a 50.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Jennifer Zachary sold 80,315 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the transaction, the executive vice president directly owned 45,509 shares of the company’s stock, valued at $6,073,631.14. This represents a 63.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is owned by insiders.
Merck & Co., Inc. Price Performance
MRK stock opened at $148.19 on Wednesday. Merck & Co., Inc. has a 12-month low of $82.01 and a 12-month high of $156.92. The stock has a market capitalization of $365.62 billion, a price-to-earnings ratio of 118.55, a PEG ratio of 6.64 and a beta of 0.21. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The firm’s 50-day moving average price is $146.22 and its two-hundred day moving average price is $129.67.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The business’s revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the business posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts predict that Merck & Co., Inc. will post 2.66 earnings per share for the current year.
Merck & Co., Inc. Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.
Merck & Co., Inc. Company Profile
Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.
Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.
Featured Articles
- Five stocks we like better than Merck & Co., Inc.
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
